Q4 and Full Year 2021

Business & Financial Presentation

February 28, 2022

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas and Decipher Bladder tests and products for use in diagnosing and treating diseases, Medicare coverage, and our commercial organization. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to our ability to launch, commercialize and receive reimbursement for our products, to successfully integrate the HalioDx and Decipher businesses and execute on our business plans; continue to scale our global operations and enhance our internal control environment; the impact of the COVID-19 pandemic and its variants on our business and general economic conditions; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022 and our Annual Report on Form 10-K to be filed for the year ended December 31, 2021. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Immunoscore, TMExplore, Brightplex, Immunosign, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

Key Takeaways

- Robust Q4 and full-year 2021 revenue growth year-over-year, despite COVID headwinds
- 2022 total revenue guidance $260M to $275M[1]
- Expect 2022 growth to be driven largely by Afirma, Decipher Urology and Biopharma
- Investing in long-term growth: Nasal Swab, nCounter menu expansion and IVD manufacturing
- Strong cash and cash equivalents position ($173M at Dec. 31, 2021)

[1] Guidance and currency rates are as of February 28, 2022 only

veracyte

Our vision is to improve outcomes for patients all over the world at every step of their journey.

Our Strategy



Q4 2021 and Full Year Revenue

Delivered Q4 2021 total revenue growth of 95% year-over-year; 2021 revenue growth of 87% compared to 2020





1. Amounts in millions. Testing, Product and BioPharma revenue rounded and summarized as presented
2. Q4 2021 and Full Year 2021 includes $4M JNJ milestone payment

Q4 2021 and Full Year 2021 Volume

Delivered testing and product volume growth of 70% year-over-year





Q4 2021 and Full Year 2021 Gross Margin

Total company gross margin, net of intangible asset amortization of 66%; benefitted from JNJ milestone





Q4 2021 Operating Expenses

Operating expenses include full quarter of HalioDx; partially offset by lower acquisition-related costs

Operating Expense by Quarter[1]



- S&M and R&D expenses increased sequentially driven by a full quarter of HalioDx expenses
- G&A expenses decreased sequentially driven by a decrease in acquisition-related costs
- Total company operating expenses in Q4 2021 included $6.5M of stock-based compensation

[1] Amounts in millions. Operating expenses rounded and summarized as presented

Q4 2021 Cash Balance

Ending 2021 cash and cash equivalents balance of $173M



- Q4 2021 cash generated from operating activities was $8.4M
- Excluding acquisition related costs, in 2021 the company generated positive cash from operating activities

[1] Cash and cash equivalents, excluding restricted cash, in millions

2022 Revenue Guidance

Initiating total revenue guidance of $260M - $275M



1. Testing, Product and Biopharma revenue rounded and summarized as presented in millions
2. Guidance and currency rates are as of February 28, 2022 only
3. 2021 included $4M JNJ milestone